Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totalling 36,600 shares, an increase of 10.2% from the August 31st total of 33,200 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 8,900 shares, the short-interest ratio is currently 4.1 days.
Eterna Therapeutics Stock Down 4.8 %
Shares of NASDAQ:ERNA traded down $0.05 during trading on Tuesday, reaching $1.00. 17,779 shares of the stock traded hands, compared to its average volume of 13,618. The stock has a market cap of $5.41 million, a P/E ratio of -0.23 and a beta of 4.43. The company has a debt-to-equity ratio of 3.03, a quick ratio of 0.37 and a current ratio of 0.37. The stock has a 50-day moving average of $1.64 and a two-hundred day moving average of $1.89. Eterna Therapeutics has a 52-week low of $0.84 and a 52-week high of $2.63.
Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($1.02) EPS for the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%. The business had revenue of $0.05 million for the quarter.
Institutional Inflows and Outflows
Eterna Therapeutics Company Profile
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Recommended Stories
- Five stocks we like better than Eterna Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How to Evaluate a Stock Before BuyingÂ
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Compound Interest and Why It Matters When Investing
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.